Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

Slides:

Advertisements

Similar presentations

Mouse strain and quality control testing: improved sensitivity of the mouse embryo assay with embryos from outbred mice Zaraq Khan, M.B.B.S., Heather S.

Advertisements

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Fertility preservation in pre-pubertal girls with cancer: the role of ovarian tissue cryopreservation W. Hamish B. Wallace, M.D., Thomas W. Kelsey, Ph.D.,

Age at menarche: a predictor of diminished ovarian function?

Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study Carolyn Gibson, M.P.H., M.S., Karen Matthews,

Akanksha Mehta, M.D., Mark Sigman, M.D. Fertility and Sterility

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Infertility evaluation and treatment among women in the United States

H. Irene Su, M. D. , M. S. C. E. , Mary D. Sammel, Sc. D. , Michael V

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Michael M. Alper, M.D. Fertility and Sterility

Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J

Hepatitis and reproduction

Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause Linlin Cui, M.D., Ph.D., Yingying.

Circulating vitamin D correlates with serum antimüllerian hormone levels in late- reproductive-aged women: Women's Interagency HIV Study Zaher O. Merhi,

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.

Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids Isabelle.

Temporal trends in clomiphene citrate use: a population-based study

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Association between socio-psycho-behavioral factors and male semen quality: systematic review and meta-analyses Ying Li, Ph.D., Hui Lin, Ph.D., Yafei.

Cosmetics use and age at menopause: is there a connection?

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

A comparison of blood spot vs

Application of redefined human chorionic gonadotropin curves for the diagnosis of women at risk for ectopic pregnancy Beata E. Seeber, M.D., Mary D.

Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with.

Pregnancy-related fibroid reduction

Ellen W. Freeman, Ph. D. , Clarisa R. Gracia, M. D. , Mary D

Transurethral partial cystectomy and laparoscopic reconstruction for the management of bladder endometriosis See-Tong Pang, M.D., Ph.D., Angel Chao,

Prospective evaluation of luteal phase length and natural fertility

Oocyte cryopreservation

How and when human chorionic gonadotropin curves in women with an ectopic pregnancy mimic other outcomes: differences by race and ethnicity Katherine.

Mieke Carine Wim Eeckhaut, Ph.D. Fertility and Sterility

Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling.

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron.

Sean Ackerman, M. D. , Julia Wenegrat, M. A. , David Rettew, M. D

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Clomiphene citrate at 50: the dawning of assisted reproduction

Using the Society for Assisted Reproductive Technology Clinic Outcome System morphological measures to predict live birth after assisted reproductive.

Use of “2-dose” regimen of methotrexate to treat ectopic pregnancy

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception Lauren N.C. Johnson,

One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above Sigal Klipstein, M.D., Meredith.

A longitudinal study of the effects of free testosterone and other psychosocial variables on sexual function during the natural traverse of menopause

Jeanne M Manson, Ph. D. , Mary D Sammel, Ellen W Freeman, Ph. D

Vasiliki A. Moragianni, M. D. , M. S. , Stephanie-Marie L. Jones, M. D

Fertility and Sterility: an evaluation

The menopausal transition

Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence

Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,

Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles Lauren Johnson, M.D., M.S.C.E., Mary D. Sammel,

Association of endometriosis with body size and figure

Ovarian cystic teratoma with a pathognomonic appearance of multiple floating balls: a case report and investigation of common characteristics of the cases.

Janet S. Carpenter, Ph. D. , R. N. , Katherine A. Guthrie, Ph. D

Current evaluation of amenorrhea

Genetic evaluation procedures at sperm banks in the United States

Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients Scott M. Nelson, Ph.D., Martina C. Messow,

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Aline Ketefian, M. D. , Jianfang Hu, Ph. D. , Alfred A. Bartolucci, Ph

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Soluble HLA-G in the peritoneal fluid of women with endometriosis

Early menopause in mothers of children with Down syndrome?

Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve Norbert.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D., Mary D. Sammel, Sc.D., Hui Lin, M.S., David W. Boorman, M.S., Clarisa R. Gracia, M.D. Fertility and Sterility Volume 98, Issue 5, Pages 1254-1259.e2 (November 2012) DOI: 10.1016/j.fertnstert.2012.07.1139 Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Antimüllerian hormone (AMH) rate of decline during the study interval for women with baseline AMH ≥1.0 ng/mL in five subgroups. Subgroups are the following (starting at lower left): ages 45–49 years, fast rate of decline; 40–44 years, fast rate of decline; 35–39 years, fast rate of decline; 40–44 years, slow rate of decline; 35–39 years, slow rate of decline. The subgroups with AMH <1.0 ng/mL at baseline had little additional AMH level decline and the curves of these subgroups were nearly identical (not shown). Fertility and Sterility 2012 98, 1254-1259.e2DOI: (10.1016/j.fertnstert.2012.07.1139) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions